Company news

Rhythm Pharmaceuticals, Inc. news in 2026

Rhythm Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

November 4, 2026

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

November 3, 2026

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

November 2, 2026

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

October 21, 2026

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

October 13, 2026

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

September 22, 2026

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

September 10, 2026

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

August 24, 2026

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

August 17, 2026

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

August 11, 2026

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

August 4, 2026

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

August 4, 2026

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 21, 2026

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

July 8, 2026

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

June 15, 2026

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

June 13, 2026

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

June 12, 2026

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

May 29, 2026

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

May 28, 2026

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

May 6, 2026

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 5, 2026

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

May 4, 2026

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

May 1, 2026

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

April 9, 2026

Rhythm Pharmaceuticals Announces Changes to Board of Directors

April 2, 2026

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

March 25, 2026

PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

March 20, 2026

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

March 18, 2026

Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

March 16, 2026

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

March 1, 2026

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

February 25, 2026

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

February 17, 2026

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

February 4, 2026

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

January 8, 2026

Calls in 2026

Decks in 2026